{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:07:54Z","timestamp":1776247674348,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015096","name":"Betta Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.eclinm.2021.101187","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T18:24:17Z","timestamp":1637346257000},"page":"101187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study"],"prefix":"10.1016","volume":"42","author":[{"given":"Rui","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weineng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haohui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.101187_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2021.101187_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fonc.2017.00080","article-title":"Targeting lung cancer stem cells: research and clinical impacts","volume":"7","author":"Zakaria","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0003","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.101187_bib0004","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2021.101187_bib0005","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0006","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.21037\/tlcr.2019.12.23","article-title":"Biosimilar candidate IBI305 plus paclitaxel\/carboplatin for the treatment of non-squamous non-small cell lung cancer","volume":"8","author":"Yang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.eclinm.2021.101187_bib0008","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0009","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"et al Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.101187_bib0010","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0011","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0012","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fonc.2020.00904","article-title":"Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0013","unstructured":"European Medicines Agency. Biosimilars in the EU. Information guide for healthcare professionals. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Leaflet\/2017\/05\/WC500226648.pdf."},{"key":"10.1016\/j.eclinm.2021.101187_bib0014","year":"2014","journal-title":"Guideline on similar biological medicinal products"},{"key":"10.1016\/j.eclinm.2021.101187_bib0015","year":"2015","journal-title":"Scientific considerations in demonstrating biosimilarity to a reference product"},{"key":"10.1016\/j.eclinm.2021.101187_bib0016","year":"2015","journal-title":"National Medical Products Administration. Draft Technical Guidelines for Research, Development and Evaluation of Biosimilars"},{"key":"10.1016\/j.eclinm.2021.101187_bib0017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/cmi.2014.6","article-title":"Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60","volume":"11","author":"Yang","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0018","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-018-3645-1","article-title":"Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects","volume":"82","author":"Zhang","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0019","author":"European Medicines","year":"2012","journal-title":"Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues"},{"key":"10.1016\/j.eclinm.2021.101187_bib0020","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-16-1010","article-title":"Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study","volume":"22","author":"He","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2021.101187_bib0021","doi-asserted-by":"crossref","first-page":"989","DOI":"10.21037\/tlcr.2019.12.23","article-title":"Biosimilar candidate IBI305 plus paclitaxel\/carboplatin for the treatment of non-squamous non-small cell lung cancer","volume":"8","author":"Yang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101187_bib0022","doi-asserted-by":"crossref","first-page":"816","DOI":"10.20892\/j.issn.2095-3941.2020.0212","article-title":"Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial","volume":"18","author":"Chu","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2021.101187_bib0023","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-18-2702","article-title":"Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study","volume":"25","author":"Thatcher","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2021.101187_bib0024","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2021.101187_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1743-7563.2011.01397.x","article-title":"Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial","volume":"7","author":"Mok","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0026","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-019-03946-8","article-title":"Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin\u00ae) in patients with advanced non-squamous non-small cell lung cancer","volume":"85","author":"Li","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0027","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2020.05.027","volume":"146","author":"Reck","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.eclinm.2021.101187_bib0028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","article-title":"Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach","volume":"81","author":"Candelaria","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0029","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/0091270011421911","article-title":"Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575","volume":"52","author":"Yan","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0030","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00228-016-2101-6","article-title":"Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies","volume":"72","author":"Reijers","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0032","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ph10010019","article-title":"Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey","volume":"10","author":"Monk","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.eclinm.2021.101187_bib0034","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12094-017-1715-1","article-title":"Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer","volume":"20","author":"Zheng","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eclinm.2021.101187_bib0035","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S1470-2045(14)70365-1","article-title":"Regulatory and clinical considerations for biosimilar oncology drugs","volume":"15","author":"Bennett","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:08:06Z","timestamp":1762888086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021004685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"alternative-id":["S2589537021004685"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101187","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101187"}}